Pieris Pharmaceuticals
Yahoo Finance • 2 years ago
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
BOSTON,MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and... Full story
Yahoo Finance • 2 years ago
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and ea... Full story
Yahoo Finance • 2 years ago
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
PRESSRELEASE OMassTherapeuticsAnnouncesAppointmentofNewBoardChair andSeries B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed... Full story
Yahoo Finance • 2 years ago
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDT Elarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continues First subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fi... Full story
Yahoo Finance • 2 years ago
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
BOSTON,MA / ACCESSWIRE /October 26,2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, c... Full story
Yahoo Finance • 3 years ago
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 /Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeut... Full story
Yahoo Finance • 3 years ago
3 Risky Stocks With Huge Potential Upside
What this does is create a pool of risky stocks with huge potential upside. The stock market tries its best to value these investments. Here's why risk-tolerant investors might want to consider shares of Pieris Pharmaceuticals (NASDAQ: PIR... Full story
